{"nctId":"NCT00335452","briefTitle":"Clopidogrel Optimal Loading Dose Usage to Reduce Recurrent EveNTs/Optimal Antiplatelet Strategy for InterventionS","startDateStruct":{"date":"2006-06"},"conditions":["Acute Coronary Disease","Angina Unstable"],"count":25086,"armGroups":[{"label":"Clopidogrel high dose treatment regimen + ASA high dose","type":"EXPERIMENTAL","interventionNames":["Drug: Clopidogrel","Drug: acetylsalicyclic acid (ASA)"]},{"label":"Clopidogrel high dose treatment regimen + ASA low dose","type":"EXPERIMENTAL","interventionNames":["Drug: Clopidogrel","Drug: acetylsalicyclic acid (ASA)"]},{"label":"Clopidogrel standard treatment regimen + ASA high dose","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Clopidogrel","Drug: acetylsalicyclic acid (ASA)"]},{"label":"Clopidogrel standard treatment regimen + ASA low dose","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Clopidogrel","Drug: acetylsalicyclic acid (ASA)"]}],"interventions":[{"name":"Clopidogrel","otherNames":["SR25990","Plavix"]},{"name":"acetylsalicyclic acid (ASA)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnosed with acute coronary disease with clinical symptoms and at least electrocardiogram changes or cardiac enzymes elevated\n\nExclusion Criteria:\n\n* Use of anticoagulants within 10 days with an international normalized ratio (INR) \\> 1.5 or planned use during the hospitalisation period\n* Administration of clopidogrel \\> 75 mg prior to randomization\n* Contraindication to clopidogrel or aspirin\n* Active bleeding or significant risk of bleeding","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"First Occurrence of CV Death / MI / Stroke - Clopidogrel Treatment Regimen Comparison","description":"The primary endpoint is the first occurrence of any of the following events:\n\n* Cardiovascular death (any death with a clear cardiovascular or unknown cause),\n* Myocardial Infarction (diagnosis of new Myocardial Infarction (MI) - nonfatal or fatal)\n* Stroke (presence of a new focal neurologic deficit thought to be vascular in origin, with signs or symptoms lasting more than 24 hours - nonfatal or fatal)\n\nreported between the randomization and Day 30 (inclusive), and validated by the blinded Event Adjudication Committee (EAC).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"557","spread":null},{"groupId":"OG001","value":"522","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"222","spread":null},{"groupId":"OG001","value":"226","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"274","spread":null},{"groupId":"OG001","value":"237","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61","spread":null},{"groupId":"OG001","value":"59","spread":null}]}]}]},{"type":"SECONDARY","title":"Occurrence of Major Bleeding - Clopidogrel Dose Regimen Comparison","description":"Major bleeding is defined as any severe bleeding (associated with any of the following: death, leading to a drop in hemoglobin ≥ 5 g/dl, significant hypotension with the need for inotropic agents, symptomatic intracranial hemorrhage, requirement for surgery or for a transfusion ≥ 4 units of red blood cells or equivalent whole blood) and other major bleeding (significantly disabling bleeding, or intraocular bleeding leading to significant loss of vision or bleeding requiring transfusion of 2-3 units of red blood cells or equivalent whole blood) after validation by the independent EAC.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"255","spread":null},{"groupId":"OG001","value":"313","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"195","spread":null},{"groupId":"OG001","value":"236","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"65","spread":null},{"groupId":"OG001","value":"83","spread":null}]}]}]},{"type":"PRIMARY","title":"First Occurrence of CV Death / MI / Stroke - ASA Dose Comparison","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"546","spread":null},{"groupId":"OG001","value":"527","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"231","spread":null},{"groupId":"OG001","value":"211","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"260","spread":null},{"groupId":"OG001","value":"251","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55","spread":null},{"groupId":"OG001","value":"65","spread":null}]}]}]},{"type":"PRIMARY","title":"First Occurrence of CV Death / MI / Stroke - Interaction Clopidogrel Treatment Regimen and ASA Dose Level","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"267","spread":null},{"groupId":"OG001","value":"290","spread":null},{"groupId":"OG002","value":"282","spread":null},{"groupId":"OG003","value":"240","spread":null}]}]}]},{"type":"PRIMARY","title":"First Occurrence of CV Death / MI / Stroke - Clopidogrel Treatment Regimen Comparison in PCI Subgroup","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"392","spread":null},{"groupId":"OG001","value":"330","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"132","spread":null},{"groupId":"OG001","value":"130","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"225","spread":null},{"groupId":"OG001","value":"172","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35","spread":null},{"groupId":"OG001","value":"28","spread":null}]}]}]},{"type":"SECONDARY","title":"Occurrence of Major Bleeding - ASA Dose Level Comparison","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"285","spread":null},{"groupId":"OG001","value":"282","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"215","spread":null},{"groupId":"OG001","value":"216","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"74","spread":null},{"groupId":"OG001","value":"73","spread":null}]}]}]},{"type":"POST_HOC","title":"Occurrence of Stent Thrombosis - Clopidogrel Treatment Regimen Comparison","description":"This includes definite stent thrombosis (confirmed by angiography or evidence of recent thrombus determined at autopsy or by examination of tissue retrieved following thrombectomy) and probable stent thrombosis (unexplained death having occurred after intracoronary stenting or, MI related to acute ischemia in the territory of the implanted stent without angiographic confirmation and in the absence of any obvious cause) after validation by the EAC.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"200","spread":null},{"groupId":"OG001","value":"135","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"111","spread":null},{"groupId":"OG001","value":"58","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"89","spread":null},{"groupId":"OG001","value":"77","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":322,"n":6312},"commonTop":[]}}}